Sugammadex: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
==Adult Dosing== | ==Adult Dosing== | ||
'''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.''' | '''IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.'''<ref>Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409</ref> | ||
*4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed | *4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed | ||
*2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed | *2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed | ||
| Line 49: | Line 49: | ||
==Comments== | ==Comments== | ||
*Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref> | *Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008<ref>[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000885/WC500052309.pdf Assessment Report for Bridion. European Medicines Agency]</ref> | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 00:36, 25 December 2016
Administration
- Type/Class: γ-cyclodextrin, antidote
- Dosage Forms:
- 200mg/2mL (100mg/mL)
- 500mg/5mL (100mg/mL)
- Routes of Administration: IV
- Common Trade Names: Bridion
Adult Dosing
IV bolus injection infused over 10 seconds via central or peripheral line with 16 mg/kg will reverse a single 1.2 mg/kg dose of rocuronium in approximately 3 minutes.[1]
- 4 mg/kg if patient has no twitch responses to train-of-four and emergent reverse is not needed
- 2mg/kg if patient has a second twitch after train of four and no emergent reversal is needed
Pediatric Dosing
- No approved dosing or usage
Special Populations
- Pregnancy Rating: There are no data on use in pregnant women
- Lactation risk: Unknown
Renal Dosing
- Adult: Unknown
- Pediatric: Unknown
Hepatic Dosing
- Adult: Unknown
- Pediatric: Unknown
Contraindications
- Allergy to class/drug and or prior documentation of hypersensitivity
Adverse Reactions
Adverse effects are described in the anesthesia literature and the most serious side effect is in patients with a known hypersensitivity to Sugammadex[2]
Serious
- Anaphylaxis (0.3%), hypersensitivity reaction
- Bradycardia (1-5%)
- Prolonged QT
Common
- Nausea/vomiting
- Headache
- Coughing
- Extremity pain
- Parosmia, hypoesthesia
Pharmacology
- Onset of action: reverses paralysis in ~3 minutes
- Half-life: 2h
- Metabolism:
- Excretion: Renal
Mechanism of Action
- Encapsulates rocuronium or vecuronium in plasma, reducing the amount of neuromuscular blocking agent available to bind to nicotinic receptors in the neuromuscular junction and thereby reversing neuromuscular blockade
Comments
- Sugammadex is only FDA approved for reversal for patients undergoing surgery. The drug has been used in Europe since 2008[3]
See Also
References
- ↑ Abrishami A et al. "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". Cochrane Database of Systematic Reviews. 2009(4). CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409
- ↑ Park J. Benefits and risks of sugammadex. Korean J Anesthesiol. 2015 Feb; 68(1): 1–2.
- ↑ Assessment Report for Bridion. European Medicines Agency